Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Heuser M, et al. Among authors: shirneshan k. Leukemia. 2015 Sep;29(9):1942-5. doi: 10.1038/leu.2015.49. Epub 2015 Feb 24. Leukemia. 2015. PMID: 25792355 No abstract available.
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M. Platzbecker U, et al. Among authors: shirneshan k. Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. Leukemia. 2013. PMID: 23354011 Free PMC article. Clinical Trial. No abstract available.
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. Braulke F, et al. Among authors: shirneshan k. Leuk Res. 2013 Aug;37(8):900-6. doi: 10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25. Leuk Res. 2013. PMID: 23623559 Clinical Trial.
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J. Braulke F, et al. Among authors: shirneshan k. Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24. Haematologica. 2015. PMID: 25344522 Free PMC article.
New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes.
Ganster C, Kämpfe D, Jung K, Braulke F, Shirneshan K, Machherndl-Spandl S, Suessner S, Bramlage CP, Legler TJ, Koziolek MJ, Haase D, Schanz J. Ganster C, et al. Among authors: shirneshan k. Genes Chromosomes Cancer. 2015 Dec;54(12):717-24. doi: 10.1002/gcc.22282. Epub 2015 Sep 23. Genes Chromosomes Cancer. 2015. PMID: 26394808
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U. Schuler E, et al. Among authors: shirneshan k. Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15. Leukemia. 2016. PMID: 26668126 Clinical Trial. No abstract available.
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann WK, Germing U, Nolte F. Mossner M, et al. Among authors: shirneshan k. Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2. Leukemia. 2016. PMID: 27133825 Clinical Trial. No abstract available.
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D. Braulke F, et al. Among authors: shirneshan k. Ann Hematol. 2017 Jun;96(6):887-894. doi: 10.1007/s00277-017-2983-0. Epub 2017 Apr 3. Ann Hematol. 2017. PMID: 28374162 Clinical Trial.
31 results